Theriva Biologics, Inc. (TOVX) is a clinical-stage biotherapeutics company. Based on the limited excerpt provided from their 10-K filing, the company operates in the biologics space. Insufficient detail is available in the provided text to describe specific products, services, or therapeutic focus areas beyond the company name and ticker symbol.
Q2 FY2026 — expected 2026-09-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001104659-26-026767 | EDGAR | 102K words |
| 2025-03-06 | 2024-12-31 | 0001410578-25-000285 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001410578-24-000293 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001410578-23-000428 | EDGAR | — |
| 2022-03-16 | 2021-12-31 | 0001410578-22-000405 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001104659-21-032150 | EDGAR | — |
| 2020-02-20 | 2019-12-31 | 0001104659-20-023415 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001144204-19-010592 | EDGAR | — |
| 2018-02-22 | 2017-12-31 | 0001144204-18-010286 | EDGAR | — |
| 2017-03-02 | 2016-12-31 | 0001144204-17-012545 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-109828 | EDGAR | 37K words |
| 2025-08-11 | 2025-06-30 | 0001410578-25-001654 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001410578-25-001242 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001410578-24-001850 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001410578-24-001342 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001410578-24-000601 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001410578-23-002348 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001410578-23-001584 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001410578-23-000987 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001410578-22-003167 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001410578-22-002238 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001410578-22-001679 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001104659-26-033051 | EDGAR | 1K words |
| 2026-03-12 | 0001104659-26-026765 | EDGAR | — |
| 2026-02-18 | 0001104659-26-016792 | EDGAR | — |
| 2026-02-12 | 0001104659-26-013907 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002750 | EDGAR | — |
| 2025-12-29 | 0001104659-25-124523 | EDGAR | — |
| 2025-12-15 | 0001104659-25-121246 | EDGAR | — |
| 2025-11-12 | 0001104659-25-109821 | EDGAR | — |
| 2025-10-29 | 0001104659-25-103774 | EDGAR | — |
| 2025-10-24 | 0001104659-25-102104 | EDGAR | — |
550 total filings indexed. 518 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000894158 |
| Ticker | TOVX |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.therivabio.com |
| Listed | 1993-04-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report